Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2005
08/09/2005US6927219 Secondary amides such as N-Adamantan-1-methyl-2-chloro-5-(3,5-dioxo-4,5-dihydro-3H- (1,2,4)triazin-2-yl)-benzamide used as antagonists for biological receptors; antiinflammatiory, anticarcinogenic or antiischemic agents
08/09/2005US6927218 Aryl N-cyanoguanidines and methods related thereto
08/09/2005US6927054 Peptide for use in the diagnosis, prevention, and treatment of inflammation, cancer, arteriosclerosis and degenerative defects
08/09/2005US6926898 Albumin fusion proteins
08/09/2005CA2310627C Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
08/09/2005CA2178603C Transdermal therapeutical system for preventing poisoning by organophosphoric neurotoxins that consists of a combination of active substances including a parasympathomimetric and a parasympatholytic agent
08/09/2005CA2168012C Polymeric matrices and their uses in pharmaceutical compositions
08/09/2005CA2109098C Activity-dependent neurotrophic factor
08/04/2005WO2005071071A1 Ptd-human choline acetyltransferase fusion protein and its application
08/04/2005WO2005070902A1 Therapeutic agents ii
08/04/2005WO2005070408A1 Stress relieving composition
08/04/2005WO2004007457A3 Substituted benzylamine derivatives and methods of use
08/04/2005US20050171464 Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
08/04/2005US20050171354 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for prophylaxis of cardiovascular disorders
08/04/2005US20050171350 Benzhydryl derivatives
08/04/2005US20050171347 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
08/04/2005US20050171346 Proteases, kinases enzyme inhibitors; cardiovascular disorders; central nervous system disorders; antiinflammatrory agents; bone disorders; infections
08/04/2005US20050171345 Pteridine compounds for the treatment of psoriasis
08/04/2005US20050171338 Mammalian tribbles signaling pathways and methods and reagents related thereto
08/04/2005US20050171286 Copolymer-1 improvements in compositions of copolymers
08/04/2005US20050171188 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
08/04/2005US20050171187 Making intermediates to alpha-ethyl-2-oxo-1-pyrrolidine acetamide, also referred to as levetiracetam an antihypoxic agent and antiischemic agent; by reduction via catalytic hydrogenation of an alkenyl intermediate
08/04/2005US20050171183 Indole-type inhibitors of p38 kinase
08/04/2005US20050171178 Exo-1-methyl-1H-imidazole-4-sulfonic acid {3-[6-ethyl-3-(2-hydroxy-indan-2-ylmethyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-phenyl}-amide; opioid receptors (mu, kappa and delta) antagonists; not substrate of the variable enzyme CYP2D6; addiction to an opiates, alcohol; obesity
08/04/2005US20050171174 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/04/2005US20050171158 1-(sulfonylaminomethylcarbonyl)-4-cyclohexylpiperidine compounds such as N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide; various diseases and disorders such as weight control, eating disorders
08/04/2005US20050171154 Carboxylic acid amides
08/04/2005US20050171153 Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
08/04/2005US20050171149 antioxidant properties and peroxisome proliferator activated receptors (PPAR) alpha and PPAR gamma activator properties; cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms, neurodegenerative, and skin disorders
08/04/2005US20050171135 1'-[4-[1-(4-fluorophenyl)-1H-indole-3-Y1]-spiro[isobenzofuran-1(3H), 4'-piperidine]hydrohalogenides
08/04/2005US20050171128 Pyrrolo[2,3-d]pyrimidine compounds
08/04/2005US20050171125 Novel alkoxypyridine-derivatives
08/04/2005US20050171118 Central nervous system, gastrointestinal and psycological disorders; such as 3-(4-chlorobenzenesulfonyl)-2-methyl-7-piperazin-1-yl-1H-indole; synthesis
08/04/2005US20050171117 Preparation of pharmaceutical salts
08/04/2005US20050171111 E.g., 4-[[5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxymethyl]-1H-imidazol-1-yl]methyl]-benzonitrile; prevents the membrane attachment of p21ras and blocks the aberrant growth of ras-transformed tumors
08/04/2005US20050171107 Crystal forms of lamotrigine and processes for their preparations
08/04/2005US20050171106 5'-((benzo)thiophen-1 or 2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] compounds, optionally tritium labeled; binding ligands for nicotinic acetylcholine receptors
08/04/2005US20050171104 Novel thyroid receptor ligands
08/04/2005US20050171103 Benzamide derivatives useful as histone deacetylase inhibitors
08/04/2005US20050171102 Semicarbazide derivatives for combating thromboembolic diseases
08/04/2005US20050171101 Neurodegenerative diseases; diseases ascribed by NMDA- and NO-induced neurotoxicity ; ischemia; antiinflammatory; anticancer; antidiabetic; 2-{3-[4-Phenyl-3,6-dihydro-1(2H)-pyridyl]propyl}-6(5H)-phenanthridinone
08/04/2005US20050171098 MCH antagonists and their use in the treatment of obesity
08/04/2005US20050171096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
08/04/2005US20050171094 Pyrrolopyrimidine derivatives
08/04/2005US20050171092 Chemical compounds
08/04/2005US20050171084 Methods of treatment with lxr modulators
08/04/2005US20050171083 Modified release pharmaceutical formulation
08/04/2005US20050171078 Cholinergic ligands at the nicotinic acetylcholine receptors; diseases related to the cholinergic system; neurodegenerative disorders; pain; antiinflammatory; diagnostic or monitoring tools using labelled forms; 3-Phenyletynyl-quinuclidin-2-ene
08/04/2005US20050171075 Substitued 19-nor-cholestenes; antineoplastic agents, wound healing agents, antiinflammatory agents; autoimmune diseases, transplant rejection inhibition, hyperplasia, graft versus host disease; increased cell growth modulation and differentiation, low calcemic activity
08/04/2005US20050171074 3 alpha-hydroxy-3 beta-methoxymethyl-substituted steroids and the use thereof
08/04/2005US20050171070 Stable salts of o-acetylsalicylic acid containing basic amino acids II
08/04/2005US20050171061 Phenylsulfanylphenyl and phenyloxyphenyl substituted piperazine compounds; glycine transport inhibitors; for the treatment of psychoses and convulsive disorders: epilepsy, spasticity, and myoclonus
08/04/2005US20050171051 Pharmaceutical composition for diabetic neuropathy
08/04/2005US20050170999 Excitatory amino acid receptor antagonists
08/04/2005US20050170384 Expression vector comprising nucleotide sequences coding protein with sequence similarities to chordin proteins for use as tool in identifying modulator for treatment and prevention of infection and metabolic disorders
08/04/2005US20050170348 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression
08/04/2005US20050170327 Isolating thrombocytes from whole blood via agglutinating and sedimenting erthrocytes; regenerative medicine; tisssue engineering
08/04/2005US20050169990 dry mixing oxycodon (opioids) with trimethylammoniumethyl methacrylate chloride, forming tablet by granulation and compression, curing the dosage form; superior to those of uncured tablets
08/04/2005US20050169983 Chewable soft capsule
08/04/2005US20050169982 Topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms; seizures, obesity, neuropathic pain, affective disorders, tobacco cessation, chronic fatigue syndrome, drug addiction; highly soluble, bioavailability
08/04/2005US20050169971 Pellet or tablet attractive to livestock masking a drug such as benazepril; animal feed substrate, intimately mixed with coated particles of a carrier material and an active ingredient casing that is coated by a masking protective layer
08/04/2005US20050169925 variable regions peptides for immunizing against amyloid plaque formation; biodrug for dementia, Alzheimer's disease, neuropathy, Down's syndrome, Creutzfeld Jacob disease, Parkinson's disease, amyotropic lateral sclerosis; neuroprotectants; hemostatic agent
08/04/2005DE102004011392A1 Schwache bis mittelstarke Opioide oder Kombinationen dieser Opioide mit Antidepressiva für die Behandlung von Depressionen, Angststörungen und Schmerzen Mild to moderately potent opioids or combinations of these opioids with antidepressants for the treatment of depression, anxiety disorders and pain
08/04/2005CA2554617A1 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
08/04/2005CA2554616A1 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
08/04/2005CA2553973A1 Methods of treatment of amyloidosis using aspartyl-protease inihibitors
08/04/2005CA2553843A1 Stress relieving composition
08/03/2005EP1559726A2 Growth differentiation factor-10
08/03/2005EP1559710A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use
08/03/2005EP1559446A1 Treating agent for diarrhea-predominant irritable bowel syndrome
08/03/2005EP1559428A1 Receptor regulator
08/03/2005EP1559424A2 The use of inhibitors of the renin-angiotensin system
08/03/2005EP1559422A1 Receptor function controlling agent
08/03/2005EP1558749A2 Atypical protein kinase c isoforms in disorders of the nervous system and cancer
08/03/2005EP1558639A2 Genes whose expression is increased in response to stimulation by corticotropin-releasing hormone
08/03/2005EP1558617A1 Amidine compounds
08/03/2005EP1558608A1 Oxindole substituted piperazine derivatives
08/03/2005EP1558600A1 Selected cgrp antagonists, method for production and use thereof as medicament
08/03/2005EP1558598A1 Triazole compounds for the treatment of dysmenorrhoea
08/03/2005EP1558595A1 Piperazinyl and diazapanyl benzamides and benzthioamides
08/03/2005EP1558591A2 Modulation of anxiety through blockade of anandamide hydrolysis
08/03/2005EP1558585A1 Neurologically-active compounds
08/03/2005EP1558577A2 Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors
08/03/2005EP1558566A1 Novel phenylnaphthalene derivatives, method for production thereof and pharmaceutical compositions comprising the same
08/03/2005EP1558259A2 Il-8 receptor antagonists
08/03/2005EP1558258A1 Use of piperazine sulfonic acid derivatives as ccr1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders
08/03/2005EP1558256A1 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof
08/03/2005EP1558252A2 Substituted furo 2,3-b] pyridine derivatives
08/03/2005EP1558251A1 Method of treatment of psychological conditions by administration of nerve growth factor
08/03/2005EP1558246A1 Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
08/03/2005EP1558230A1 Spirocyclopropyl amides and acids and their therapeutic applications
08/03/2005EP1558219A1 Pharmaceutical formulation of olanzapine
08/03/2005EP1558080A2 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
08/03/2005EP1438307B1 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist
08/03/2005EP1399446B1 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders
08/03/2005EP1392347B1 Preventing cell death using segments of neural thread proteins
08/03/2005EP1330455B1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
08/03/2005EP1330166B1 Food grade transglutaminase inhibitor and uses thereof
08/03/2005EP1287017B1 2-substituted pregna-1,3,5(10)-triene and chola-1,3,5(10)-triene derivatives and their biological activity
08/03/2005EP1237567B1 Method for administering a cytokine to the central nervous system and the lymphatic system
1 ... 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 ... 1833